|
Brecon appoints new Head of Clinical Trials
Services
Brecon Pharmaceuticals launches Hereford
recruitment drive
Total Show Press Release
Brecon's labelling service enhanced
Brecon Pharmaceuticals opens new Analytical
Lab
Optimising the Value of Outsource Partners
New SV2 boosts Brecons bottling capacities
Planning go-ahead for major new facility
Brecon
appoints new Head of Clinical Trials Services
Leading
pharmaceutical outsource services provider Brecon Pharmaceuticals
has appointed Dr Susan Miles as Head of Clinical Trials Services.
Sue Miles is a
graduate from Cambridge University with a PhD from the Faculty
of Medicine at Edinburgh University. She was previously Chief
Executive Officer of Quantum Research UK, which provides electrocardiography,
respiratory and blood pressure monitoring support for the
clinical trials industry.
Commenting on the
new appointment, Brecon’s Chief Executive John Bath
said, “Clinical Trials Services has become a major area
of business growth for us. We already have a well-respected
presence in this market and offer excellent quality, service
and value for our customers. We are delighted that we have
someone with Sue’s extensive market experience to head
up the team.”
Sue Miles
believes Brecon is well placed to capitalise on the many opportunities
that will result from the introduction of the new EC Clinical
Trials Directive. She said, “I am looking forward to
supporting Brecon in the development of its Clinical Trials
Services. The new EC Directive will make choosing a clinical
trial service provider an even more crucial decision and I
believe Brecon is well placed to meet customers’ demands.”
19 April 2021
Back
to top
Brecon
Pharmaceuticals launches Hereford recruitment drive
Brecon
Pharmaceuticals Ltd, one of the UK’s leading service
providers to the global pharmaceutical industry, is holding
a recruitment event in Hereford on Wednesday 14 April to highlight
the many new job opportunities that are being created by its
major new expansion programme.
Over the next 12 months Brecon will be doubling
the size of its existing operation in Hay-on-Wye with the
development of a major new production and warehouse facility.
Brecon currently employs over 230 people from throughout the
region and the state-of-the-art development will create up
to 100 new jobs, which will confirm Brecon’s position
as a leading employer in the region.
The recruitment event is being held at The
Green Dragon Hotel in Hereford on Wednesday 14 April from
8.30 am to 7.30 pm. Members of Brecon’s team will be
on hand to answer any queries and to advise on the benefits
that the company provides its employees. Brecon’s CEO
John Bath will be attending the event and will be giving a
series of short presentations throughout the day at 11am,
1pm, 4pm and 6 pm, to illustrate the company’s future
development plans.
Brecon currently attracts its workforce from
a wide area - from the Valleys in the South to Leominster
in the North. It has developed a strong reputation as a leading
employer in the region through the provision of excellent
career opportunities, a modern and friendly working environment
and good benefit packages for its employees.
Brecon’s Personnel Manager Pauline Tarrant
believes that Hereford is a key area for the company’s
recruitment drive. She said, “Brecon has expanded rapidly
in recent
years and we have attracted employees from throughout the
region. Hereford is only 20 miles from our facility in Hay-on-Wye
and we will be offering transport links for those who join
us. Our major new development will create up to 100 new jobs
in a range of areas from production through to administration.
We welcome visitors to our event on 14 April and look forward
to telling them all about the many opportunities that Brecon
can provide.”
5 April 2021
Back
to top
Total Show Press Release -
Brecon Pharmaceuticals presents a trio of major new developments
for 2004
STAND IG80 - HALL 1
Leading
pharmaceutical outsource services provider, Brecon Pharmaceuticals
Ltd will be presenting a trio of major new business developments
at the Total Packaging and Processing Exhibition at NEC 29
March - 1 April 2004.
Brecon’s
stand IG80 is situated in Hall 1 and visitors to the stand
will be introduced to the details of the company’s major
new development programme for 2004/5, which includes:
Major New Expansion
Brecon is doubling the size of its operation at the Wye Valley
Business Park to cater for its continued growth. The construction
of a new 45,000 sq ft business unit begins in late Spring
2004 and will create new state-of-the-art production and warehouse
facilities to complement Brecon’s existing operation.
A
major recruitment drive is under way to support the new development
that will ultimately take Brecon’s workforce to over
330 personnel, making it one of the largest employers in the
region.
A
scale model of the new development will be available on Brecon’s
stand to illustrate the plans in detail.
Launch of New Analytical Laboratory
Brecon launched a new purpose-built analytical laboratory
at the start of 2004. The 95 sq m state-of-the-art facility
provides a wide range of services to match the needs of multi-national
clients, virtual organisations and global pharmaceutical companies.
Brecon’s customers can now benefit from an extensive
range of clinical trial services including simple identification
testing and analytical method transfers through to complete
finished product and ICH stability testing.
New Child-Resistant/Senior Friendly (CRSF) Blister
Pack Capabilities
Following the MHRA announcement to make CRSF packaging a legal
requirement on certain blister packs, Brecon Pharmaceuticals
is delighted to announce that it is the first UK company to
introduce BS 8404 approved CRSF blister pack capabilities
in-line, using the latest Pill Protect ™ technology.
Pill Protect ™ will be joining Brecon’s team on
the stand to illustrate this latest CRSF pack solution.
Brecon
Pharmaceuticals -
Serving the Pharmaceutical Industry with Confidence
March
2004
Back
to top
Brecon's
labelling service enhanced
Specialist
pharmaceutical outsource packaging company Brecon Pharmaceuticals
Ltd has upgraded its clinical trial labelling capabilities
with the recent installation of the latest MAP80 PRISYM 2000
software to provide label design, printing and generation
of randomisations.
The MAP80 software has been installed in Brecon’s
dedicated labelling suite, which has two printing areas and
a separate checking area for increased security.
The new system is one of the most powerful
and flexible labelling and product identification software
packages available and is fully compatible with Windows 2000
and NT. Its capabilities include differing levels of access,
assigned through restricted password controls and the ability
to create varying label designs, i.e. single label, 2-Part
label and upwards. The system can also provide multi-language
designs, which can achieve most true type fonts with international
character support.
The system
is able to generate randomisations for parallel, crossover,
scrambled and alpha-numeric trials. Other features available
are bar coding, including variable bar codes, any form of
keyboard prompts, sequential numbering and graphic formats
which can be exported for customer approval without compromising
version control. The system also provides audit trails for
traceability of tasks undertaken by all personnel.
Brecon’s Operations
Director Andrew Billington believes the new system sets the
industry standard and further expands the productivity of
Brecon’s clinical trials operations. He said, “We
commonly use databases for trials where the information on
each pack or bottle may vary, with different patient or pack
numbers. Some projects may require up to 5000 labels, all
of which may have differing information, but must look identical
for blinding purposes. This is particularly important when
placebos or different strengths of active drugs are used,
as the packs must be indistinguishable. The new system provides
the precision label printing we require using a validatable
procedure.”
5 March
2004
Back
to top
Brecon
Pharmaceuticals opens new Analytical Lab
Brecon
Pharmaceuticals Ltd has begun 2004 with the launch of its
new purpose-built analytical laboratory, which offers customers
access to the highest quality clinical trials, commercially
packed product or stand-alone analytical services.
The 95 sq m state-of-the-art
facility provides a wide range of services to match the needs
of multi-national clients, virtual organisations and global
pharmaceutical companies. Brecon’s customers can benefit
from an extensive range of clinical trial services including
simple identification testing and analytical method transfers
through to complete finished product and ICH stability testing.
The new lab aims
to be compliant with current European Good Manufacturing Practice
(GMP), ICH and FDA requirements, which will enable Brecon
to provide stability testing and studies to full ICH standard.
Method validation or the further development and updating
of methods can also be offered, together with extra validation
to GMP standards as required.
To maximise
the versatility of the lab, additional facilities have been
incorporated including a dark room for light sensitive products,
a large fume cupboard and a containment room for cytotoxic
drugs. The containment room has a dedicated, negative pressure
HEPA filtered air-handling system for the preparation and
analysis of less well characterised development drugs.
The lab equipment has been specified to the highest standards
and features: flexible HPLCs for method development, semi
micro analytical balance equipment, Coulometric Karl Fischer
apparatus, dissolution baths, disintegration apparatus, hardness
testers, a friabulator and colour meter together with equipment
to carry out a wide range of pharmacopaeial analysis.
The air-conditioned
facility can house up to eight analysts with the capacity
to expand to 16 analysts when required. The analyst team can
provide customers with an extensive report writing service
covering protocol generation, certificates of analysis, method
transfer, validation and ICH stability reports.
Manager
of Quality Services, Dr Karl Fry QP heads up the new analytical
team. He believes the new lab positions Brecon at the forefront
of the industry. He said, “This is an exciting development
for Brecon and one that I believe will prove popular with
existing and future clients”.
Jan 2004
Back
to top
22nd January
2004
Back
to top
New
SV2 boosts Brecons bottling capacities
Leading
pharmaceutical outsource packaging company Brecon Pharmaceuticals
Ltd, has increased its bottling capabilities with the introduction
of a new Swiftpack SV2-12-EFS to complement its existing bottling
lines.
The advanced new SV2, which handles a wide
range of bottle and cap designs including both screw on and
push on, has been integrated into Brecon’s automatic
line to provide capper, checkweigher, labeller, cartonner
and bandwrapper capabilities. Both the cartonner and labeller
systems are fitted with Pharmacode e and other component verification
systems.
The new SV2 also incorporates an electrostatic
counting system rather than a traditional visual system. This
new system significantly increases its product sensitivity
and enables it to detect and reject any minute physical characteristics
of non-conforming products, such as broken tablets
The new high-speed line, which handles up
to 55 bottles per minute, has been installed in a purpose
built cubicle in Brecon’s new production facility, which
operates under class 8 (ISO 14644-1) clean room conditions.
Commenting on the new line, Brecon’s
Operations Director Andrew Billington said, “The new
high speed system has proved extremely efficient in our initial
production runs. During the validation process we found that
the advanced detection facility was even able to detect product
that had been exposed to any moisture though being held in
a bare hand or left exposed to the atmosphere. The new SV2
is valuable addition to our existing bottling line and has
enhanced our speed and efficiency for customers on a wide
range of bottle and cap designs.”
18 January
2004
Back
to top
Planning
go-ahead for major new facility
Brecon
Pharmaceuticals Ltd has gained planning permission for a new
factory and warehouse facilities at its Wye Valley Business
Park site in Hay-on-Wye. The company currently employs 235
staff and this latest expansion would see as many as 115 further
jobs created.
Brecon
is already Hay-on-Wye’s largest employer and the company
continues to expand in terms both of capacity and capabilities
in line with the increasing demand in the market for its high
quality services.
Permission
was granted at a meeting of the Brecon Beacons National Park’s
planning control committee, where member were told the expansion
would be good for the town. Reported in the Brecon & Radnor
Express, Park member, Ross Murray said: “The people
of Hay must think that Christmas has come early. It is an
extremely positive thing for a small Mid-Wales market town
to have an employer of this quality”.
The newspaper
says Brecon chairman, Leon Morelli, told the meeting that
the company is a key figure in the town’s economy, “Our
further investment is vital to the wealth of the our local
economy. We offer secure, well paid jobs with career potential
and profit share for all employees.”
The committee
also heard that Brecon was committed to being a good neighbour.
“We hold the ISO14001 environmental standard which requires
us publicly to commit to improve over time as an integral
part of our business plan. That commitment makes us good neighbours,”
said Mr Morelli.
This latest
development has been prompted by ongoing growth in demand
for Brecon’s clinical trial supply and commercial packaging
services and further supports the company’s declared
mission of “Growth through Excellence”.
Chief
Executive John Bath said: “Brecon has a fundamental
commitment to quality in every area of our operations. We
have built-up a reputation for delivering the highest possible
standard of service at competitive prices, and this is now
being reflected in the level of demand we are experiencing.
These new facilities will enable us continue serving our customers
to the levels they expect, while offering them even greater
flexibility and capabilities.”
3rd October 2003
Back
to top
|